Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.

Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based onmyvac ® platform  Strasbourg, France, April 1, 2025, 5:45 p.m. CET — Transgene ...

Discover why John B. Sanfilippo & Son might be an undervalued gem. Learn about its strong dividend yield, growth metrics, and ...

Cannabis Growth Cannabis has been a booming industry in the USA and many other countries in the past decade. This followed a slow, but steady trend toward full legalization, even if doing so at the US ...

Proof of principle data from Phase I part of the Phase I/II trial of TG4050 in the adjuvant setting of head and neck cancer. All TG4050-treated patients remained disease-free after median follow-up of ...

IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing fro ...

A recent study released by researchers from Pohang University of Science and Technology (POSTECH) opens the door for more ...

As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new jobs at its manufacturing site at the Philadelphia Navy Yard, writes John ...

We've identified the following companies as similar to Scandion Oncology A/S because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to ...

OSLO, Norway, March 20, 2025 /PRNewswire/ -- Agilyx ASA (OSE: AGLX) (OTCQX: AGXXF) ("Agilyx" or "the company") announces that production of styrene via Styrenyx, its proprietary polystyrene ...

Some hoped the biotech's stock could soar due to another company acquiring it, but that now seems unlikely. The drugmaker is a fairly attractive long-term option regardless of Wall Street's price ...

A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently ...